ClinicalTrials.gg
RecruitingNCT07776756Updated Aug 20, 2026

Enamel Matrix Derivative and Xenograft for Mandibular Molar Furcation Defects

An interventional study of Periodontal Regenerative Surgery With Xenograft and Enamel Matrix Derivative and Periodontal Regenerative Surgery With Xenograft and Collagen Membrane in Class II Furcation Defect, sponsored by University of Medicine and Pharmacy at Ho Chi Minh City. Recruiting at 1 site in Vietnam. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by University of Medicine and Pharmacy at Ho Chi Minh City · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized controlled clinical trial aims to compare two regenerative surgical approaches for the treatment of mandibular molar Class II furcation defects in patients with periodontitis. Eligible furcation defects will be randomly assigned to receive either xenograft bone combined with enamel matrix derivative (EMD) or xenograft bone combined with a collagen membrane. Both approaches are used to support periodontal tissue regeneration.

Participants will be followed for approximately 7 months. The study will evaluate postoperative pain and patient-reported satisfaction, periodontal clinical parameters, changes in furcation defect volume and relative bone density on cone-beam computed tomography (CBCT), and changes in gingival crevicular fluid TWEAK levels. Clinical and radiographic outcomes will be assessed before surgery and during follow-up, including at 3 and 6 months after surgery.

The study is intended to determine whether xenograft bone combined with EMD provides clinical, radiographic, biological, and patient-reported outcomes comparable or superior to xenograft bone combined with a collagen membrane in the regenerative treatment of mandibular molar Class II furcation defects.

Read the detailed description

This is a randomized controlled clinical trial involving patients with periodontitis who have Class II furcation defects affecting mandibular first and/or second molars. A total of 24 eligible teeth are planned, with 12 teeth assigned to each treatment group.

Before surgery, participants will undergo clinical periodontal examination, intraoral three-dimensional scanning, CBCT imaging, and gingival crevicular fluid collection. Clinical measurements include plaque index (PI), gingival index (GI), probing pocket depth (PPD), vertical clinical attachment loss (VCAL), and horizontal clinical attachment loss (HCAL).

Eligible defects will be randomly assigned to one of two regenerative surgical treatments. Following flap elevation, debridement, root surface cleaning, and conditioning with 24% EDTA, the control group will receive xenograft bone covered with a resorbable collagen membrane. The experimental group will receive enamel matrix derivative applied to the defect-related root surface, followed by xenograft bone combined with enamel matrix derivative. The flap will then be repositioned and sutured.

Postoperative pain will be assessed using a visual analog scale, together with analgesic consumption and patient-reported satisfaction regarding swelling and chewing ability. Participants will return for follow-up at approximately 2 weeks, 1 month, 3 months, and 6 months after surgery. Gingival crevicular fluid will be collected during follow-up for measurement of TWEAK concentration.

At 3 months, selected periodontal and biological assessments will be repeated. At 6 months, periodontal clinical measurements, intraoral three-dimensional scanning, furcation defect classification, and CBCT imaging will be repeated to evaluate changes in defect volume and relative bone density.

The primary purpose of the study is to compare the regenerative effectiveness of xenograft bone combined with enamel matrix derivative with that of xenograft bone combined with a collagen membrane for the treatment of mandibular molar Class II furcation defects.

02

Conditions studied

  • Class II Furcation Defect

Browse trials for

Keywords

  • Periodontal Regeneration
  • Enamel Matrix Derivative
  • Xenograft
  • Emdogain
  • Collagen Membrane
  • Class II Furcation
  • Mandibular Molar
  • Cerabone
  • Bio-Gide
  • TWEAK
  • TNF-like weak inducer of apoptosis (TWEAK)
03

In context

Furcation Defects

42 studies on the registry are indexed under Furcation Defects; 13 are open to participants now.

This study's planned enrollment of 24 is below the median of 27 across 38 interventional studies indexed under Furcation Defects.

Browse Furcation Defects studies →

Lead sponsor

University of Medicine and Pharmacy at Ho Chi Minh City is the lead sponsor of 127 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Full-mouth plaque score (FMPS) ≤ 20%.
  • Full-mouth bleeding score (FMBS) ≤ 20%.
  • Willingness to participate in the study and provide .
  • Mandibular first and/or second molar with a buccal Class II furcation defect classified as subgroup A2 or B2.
  • Probing pocket depth (PPD) ≥ 5 mm at the eligible furcation site.
  • Keratinized gingival height ≥ 2 mm at the eligible site.
  • No gingival recession extending apically beyond the buccal furcation roof; the furcation entrance must not be clinically exposed above the gingival margin.

Exclusion criteria

Exclusion Criteria:

  • Systemic diseases or conditions that may affect periodontal treatment outcomes, including uncontrolled diabetes mellitus, heart disease requiring anticoagulant therapy, hematologic disorders, or immunodeficiency.
  • Pregnancy or breastfeeding.
  • Untreated endodontic pathology involving the study tooth.
  • Class III furcation involvement according to the Hamp classification.
  • Untreated occlusal trauma involving the study tooth.
  • Grade II tooth mobility that has not been stabilized by splinting, or Grade III tooth mobility according to the Miller classification.
  • Defective restorations at the surgical site, including overhanging, bulky, or poorly adapted restorations.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Xenograft + Enamel Matrix Derivative

    Procedure: Periodontal Regenerative Surgery With Xenograft and Enamel Matrix Derivative

  • Active comparator
    Xenograft + Collagen Membrane

    Procedure: Periodontal Regenerative Surgery With Xenograft and Collagen Membrane

Interventions

  • ProcedurePeriodontal Regenerative Surgery With Xenograft and Enamel Matrix Derivative

    Periodontal regenerative surgery is performed using xenograft bone combined with enamel matrix derivative (EMD). After flap elevation, thorough defect debridement, and root surface conditioning with 24% EDTA for 2 minutes, EMD is applied to the root surface associated with the furcation defect. The xenograft bone is mixed with EMD and placed to completely fill the defect. The flap is then repositioned and sutured.

  • ProcedurePeriodontal Regenerative Surgery With Xenograft and Collagen Membrane

    Periodontal regenerative surgery is performed using xenograft bone combined with a resorbable collagen membrane. After flap elevation, thorough defect debridement, and root surface conditioning with 24% EDTA for 2 minutes, the xenograft bone is mixed with sterile saline and placed to completely fill the furcation defect. A trimmed resorbable collagen membrane is positioned to completely cover the defect and secured before flap repositioning and suturing.

06

What researchers measure

Primary outcomes

  1. Change in Probing Pocket Depth (PPD)

    Probing pocket depth (PPD) is measured in millimeters from the gingival margin to the base of the periodontal pocket using a UNC-15 periodontal probe at the mesiobuccal, buccal, and distobuccal sites of the treated tooth. Measurements are standardized using an individualized acrylic stent. The change in PPD from baseline to 6 months after surgery will be compared between the two treatment groups.

    Time frame: Baseline and 6 months after surgery

  2. Change in Horizontal Clinical Attachment Loss (HCAL)

    Horizontal clinical attachment loss (HCAL) is measured in millimeters from the buccal entrance of the furcation to the deepest horizontal point of the furcation defect using a Nabers periodontal probe and an individualized acrylic stent.

    Time frame: Baseline and 6 months after surgery

Secondary outcomes

  1. Change in Vertical Clinical Attachment Loss (VCAL)

    Time frame: Baseline and 6 months after surgery

  2. Change in Buccal Gingival Recession (REC)

    Time frame: Baseline, 3 months, and 6 months after surgery

  3. Change in Plaque Index (PI)

    Time frame: Baseline, 3 months, and 6 months after surgery

  4. Change in Gingival Index (GI)

    Time frame: Baseline and 6 months after surgery

  5. Change in Furcation Defect Volume on CBCT

    Time frame: Baseline and 6 months after surgery

  6. Change in Relative Bone Density on CBCT

    Time frame: Baseline and 6 months after surgery

  7. Change in Gingival Crevicular Fluid TWEAK Concentration

    Time frame: Baseline, 1 month, and 3 months after surgery

  8. Postoperative Pain Assessed by Visual Analog Scale (VAS)

    Time frame: 12 hours, 24 hours, and 72 hours after surgery

  9. Postoperative Analgesic Consumption

    Time frame: During the first 3 days after surgery

  10. Patient Satisfaction With Postoperative Swelling

    Patient-reported satisfaction with postoperative swelling will be assessed using a 5-point Likert scale, where 1 = very dissatisfied, 2 = dissatisfied, 3 = neutral, 4 = satisfied, and 5 = very satisfied. Higher scores indicate better satisfaction (better outcome).

    Time frame: 3 and 7 days after surgery

  11. Patient Satisfaction With Chewing Ability

    Patient-reported satisfaction with chewing ability after surgery will be assessed using a 5-point Likert scale, where 1 = very dissatisfied, 2 = dissatisfied, 3 = neutral, 4 = satisfied, and 5 = very satisfied. Higher scores indicate better satisfaction (better outcome).

    Time frame: 3 and 7 days after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07776756
Responsible party
Vy Truong Tuong Huynh (Doctor of Dental Surgery, University of Medicine and Pharmacy at Ho Chi Minh City) — Principal investigator
First posted
Aug 20, 2026
Start date
Jun 29, 2026
Primary completion
Sep 29, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Aug 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion